News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,124 Results
Type
Article (39650)
Company Profile (286)
Press Release (647188)
Section
Business (204182)
Career Advice (2003)
Deals (35392)
Drug Delivery (85)
Drug Development (80927)
Employer Resources (168)
FDA (16112)
Job Trends (14863)
News (345041)
Policy (32468)
Tag
Academia (2558)
Alliances (49185)
Alzheimer's disease (1242)
Approvals (16042)
Artificial intelligence (131)
Bankruptcy (352)
Best Places to Work (11580)
Biotechnology (206)
Breast cancer (120)
Cancer (1086)
Cardiovascular disease (97)
Career advice (1668)
Cell therapy (235)
Clinical research (64327)
Collaboration (388)
Compensation (200)
COVID-19 (2532)
C-suite (95)
Data (1126)
Diabetes (152)
Diagnostics (6141)
Earnings (84872)
Employer resources (146)
Events (109717)
Executive appointments (311)
FDA (16653)
Funding (352)
Gene therapy (178)
GLP-1 (581)
Government (4331)
Healthcare (18699)
Infectious disease (2617)
Inflammatory bowel disease (106)
Interviews (311)
IPO (16307)
Job creations (3640)
Job search strategy (1425)
Layoffs (413)
Legal (7862)
Lung cancer (170)
Manufacturing (177)
Medical device (13193)
Medtech (13198)
Mergers & acquisitions (19160)
Metabolic disorders (402)
Neuroscience (1523)
NextGen Class of 2024 (6522)
Non-profit (4474)
Northern California (1481)
Obesity (232)
Opinion (180)
Patents (102)
People (56392)
Phase I (19980)
Phase II (28339)
Phase III (21114)
Pipeline (458)
Postmarket research (2557)
Preclinical (8524)
Radiopharmaceuticals (236)
Rare diseases (220)
Real estate (5907)
Regulatory (21543)
Research institute (2329)
Resumes & cover letters (350)
Southern California (1301)
Startups (3576)
United States (13503)
Vaccines (548)
Weight loss (168)
Date
Today (105)
Last 7 days (690)
Last 30 days (3722)
Last 365 days (35735)
2024 (32791)
2023 (40159)
2022 (51251)
2021 (55795)
2020 (54158)
2019 (46604)
2018 (35088)
2017 (32171)
2016 (31585)
2015 (37659)
2014 (31432)
2013 (26461)
2012 (28657)
2011 (29324)
2010 (27376)
Location
Africa (714)
Arizona (192)
Asia (37223)
Australia (6089)
California (3330)
Canada (1293)
China (249)
Colorado (146)
Connecticut (152)
Europe (79892)
Florida (462)
Georgia (116)
Illinois (344)
Indiana (197)
Kansas (96)
Maryland (575)
Massachusetts (2619)
Michigan (157)
Minnesota (273)
New Jersey (955)
New York (964)
North Carolina (703)
Northern California (1481)
Ohio (139)
Pennsylvania (845)
South America (1094)
Southern California (1301)
Texas (464)
Utah (90)
Washington State (362)
687,124 Results for "mivi neuroscience inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
MIVI Neuroscience™ Presents Primary Endpoint Results from the EvaQ Trial — at the 2024 International Stroke Conference
MIVI Neuroscience, Inc. (Eden Prairie, MN) announces the primary endpoint results of its EvaQ Trial, a prospective, multi-center, global, single arm, FDA-regulated IDE trial study to evaluate the safety and effectiveness of the MIVI Q™ Revascularization System for treating acute ischemic stroke.
February 8, 2024
·
3 min read
BioMidwest
Clinical Trial Enrollment Complete for Study of MIVI Q™ Revascularization System that Treats Acute Ischemic Stroke
MIVI Neuroscience, Inc., innovator of next-generation neurointerventional medical devices, today announced that it has completed enrollment in the company’s clinical trial to assess the safety and effectiveness of the Q™ Revascularization System for the treatment of acute ischemic stroke (EVAQ Trial).
May 3, 2023
·
2 min read
Press Releases
Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
October 23, 2024
·
4 min read
Deals
Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.
Numinus Wellness Inc. announces today that it has entered into an agreement to divest its holdings in Alto Neuroscience Inc. (“Alto”), a clinical-stage biopharmaceutical company.
February 1, 2024
·
3 min read
Press Releases
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
September 30, 2024
·
5 min read
Biotech Bay
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York.
May 29, 2024
·
1 min read
Business
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company’s leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO).
May 21, 2024
·
3 min read
Business
ProMIS Neurosciences, Inc. Announces Leadership Transition
ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced a strategic leadership change.
January 3, 2024
·
6 min read
Press Releases
Alto Neuroscience to Participate in Upcoming Investor Conferences
November 4, 2024
·
1 min read
Press Releases
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
November 5, 2024
·
6 min read
1 of 68,713
Next
